Harvard’s David Sinclair and City of Hope’s Charles Brenner often talk about NAD boosters as potential help for those fighting COVID-19. A new Phase-2 clinical study suggests they may be correct. The study focused on patients with mild-to-moderate COVID-19 symptoms who received the standard of care in combination with a nutritional protocol including Nicotinamide Riboside “NR” (FAQs) (Reviews). Below is a concise explanation of the study – and, more important, NAD expert Dr Brenner’s take on the findings (see the last line).
Oppenheimer Analyst Brian Nagel:
“Early today, ChromaDex announced the results of a Phase-2 clinical study which shows that nutritional protocol including the company’s proprietary Nicotinamide Riboside (NR) plus standard-of-care reduces recovery time in mild-to-moderate COVID-19 patients by nearly one-third.
Study Suggests NR Helps to Lessen COVID-19 Recovery Time: Results of a Phase 2 clinical study show that patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time (6.6 days vs. 9.3 days) when receiving the standard of care in combination with a nutritional protocol including NR.
NR/COVID-19 Study Robust. The clinical study included nearly 100 patients and was conducted in partnership with ScandiBio Therapeutics, at a research hospital in Istanbul, Turkey. A Phase 3 study is expected to commence soon.
Dr Charles Brenner — NAD Expert and Discoverer of NAD Booster Nicotinamide Riboside (NR) used in the Study:
RELATED:
- FAQs on taking NAD boosting vitamin supplement Nicotinamide Riboside (NR) can be found HERE.
- NR supplementation may have helped sufferers of these diseases & conditions (Consumer Reviews)
FOLLOW us on Twitter @RaisingNAD
6 Pingbacks